Avadel Pharmaceuticals (AVDL) Financials

$9.05 +0.35 (+4.02%)

As of 11:27 AM Eastern

Annual Income Statements for Avadel Pharmaceuticals

This table shows Avadel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-137	-160	-49
Consolidated Net Income / (Loss)	-137	-160	-49
Net Income / (Loss) Continuing Operations	-137	-160	-49
Total Pre-Tax Income	-111	-161	-49
Total Operating Income	-99	-138	-42
Total Gross Profit	0.00	27	154
Total Revenue	0.00	28	169
Operating Revenue	0.00	28	169
Total Cost of Revenue	0.00	0.85	15
Operating Cost of Revenue	0.00	0.85	15
Total Operating Expenses	99	165	196
Selling, General & Admin Expense	75	152	181
Research & Development Expense	21	13	15
Restructuring Charge	3.35	0.00	0.00
Total Other Income / (Expense), net	-13	-23	-6.68
Interest Expense	12	23	11
Interest & Investment Income	-0.54	0.09	4.15
Income Tax Expense	26	-0.50	-0.25
Basic Earnings per Share	($2.29)	($2.00)	($0.51)
Weighted Average Basic Shares Outstanding	60.09M	80.17M	95.14M
Diluted Earnings per Share	($2.29)	($2.00)	($0.51)
Weighted Average Diluted Shares Outstanding	60.09M	80.17M	95.14M
Weighted Average Basic & Diluted Shares Outstanding	64.48M	90.58M	96.63M

This table shows Avadel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-20	-27	-31	-64	-36	-29	-27	-14	-2.63	-5.04
Consolidated Net Income / (Loss)	-20	-27	-31	-64	-36	-29	-27	-14	-2.63	-5.04
Net Income / (Loss) Continuing Operations	-20	-27	-31	-64	-36	-29	-27	-14	-2.63	-5.04
Total Pre-Tax Income	-20	-27	-31	-64	-36	-29	-27	-14	-2.54	-4.96
Total Operating Income	-17	-23	-28	-50	-35	-25	-26	-13	-0.33	-3.30
Total Gross Profit	0.00	-	0.00	1.46	6.90	19	26	39	44	46
Total Revenue	0.00	-	0.00	1.50	7.01	19	27	42	50	50
Operating Revenue	0.00	-	0.00	1.50	7.01	19	27	42	50	50
Total Cost of Revenue	0.00	-	0.00	0.04	0.12	0.69	1.52	2.79	6.16	4.81
Operating Cost of Revenue	0.00	-	0.00	0.04	0.12	0.69	1.52	2.79	6.16	4.81
Total Operating Expenses	17	23	28	51	42	44	52	51	44	49
Selling, General & Admin Expense	14	17	24	47	39	41	49	47	40	45
Research & Development Expense	2.93	6.24	3.83	4.22	2.85	2.36	3.07	4.05	3.80	4.27
Total Other Income / (Expense), net	-3.12	-4.33	-3.07	-15	-1.08	-3.99	-1.21	-1.59	-2.21	-1.67
Interest Expense	3.56	3.26	3.26	15	1.98	2.35	2.59	2.72	2.82	2.70
Interest & Investment Income	0.45	-1.07	0.19	0.62	0.90	-1.63	1.38	1.13	0.61	1.04
Income Tax Expense	0.07	0.09	-0.58	0.09	0.09	-0.10	0.09	-0.51	0.09	0.08
Basic Earnings per Share	($0.33)	($0.44)	($0.48)	($0.83)	($0.41)	($0.28)	($0.30)	($0.14)	($0.03)	($0.04)
Weighted Average Basic Shares Outstanding	60.20M	60.09M	63.89M	77.25M	89.38M	80.17M	91.69M	96.15M	96.30M	95.14M
Diluted Earnings per Share	($0.33)	($0.44)	($0.48)	($0.83)	($0.41)	($0.28)	($0.30)	($0.14)	($0.03)	($0.04)
Weighted Average Diluted Shares Outstanding	60.20M	60.09M	63.89M	77.25M	89.38M	80.17M	91.69M	96.15M	96.30M	95.14M
Weighted Average Basic & Diluted Shares Outstanding	61.78M	64.48M	76.77M	89.37M	89.81M	90.58M	96.12M	96.27M	96.36M	96.63M

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	23	-43	20
Net Cash From Operating Activities	-70	-129	-47
Net Cash From Continuing Operating Activities	-70	-129	-47
Net Income / (Loss) Continuing Operations	-137	-160	-49
Consolidated Net Income / (Loss)	-137	-160	-49
Depreciation Expense	1.49	1.77	2.68
Amortization Expense	6.05	2.80	0.00
Non-Cash Adjustments To Reconcile Net Income	7.01	29	20
Changes in Operating Assets and Liabilities, net	53	-1.74	-21
Net Cash From Investing Activities	80	-50	52
Net Cash From Continuing Investing Activities	80	-50	52
Purchase of Property, Plant & Equipment	-0.72	0.00	0.00
Purchase of Investments	-3.41	-237	-276
Sale and/or Maturity of Investments	84	187	328
Net Cash From Financing Activities	15	135	16
Net Cash From Continuing Financing Activities	15	135	16
Repayment of Debt	-13	-43	0.00
Issuance of Debt	0.00	30	0.00
Issuance of Common Equity	28	148	16
Other Net Changes in Cash	-0.66	0.46	-0.64
Cash Interest Paid	9.66	5.25	7.18
Cash Income Taxes Paid	-29	0.00	0.00

This table details how cash moves in and out of Avadel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	6.59	13	9.41	-33	1.83	-21	4.63	-6.95	-0.27	23
Net Cash From Operating Activities	-6.80	-15	-30	-32	-38	-28	-30	-18	-6.89	7.87
Net Cash From Continuing Operating Activities	-6.80	-15	-30	-32	-38	-28	-30	-19	-6.44	7.87
Net Income / (Loss) Continuing Operations	-20	-27	-31	-64	-36	-29	-27	-14	-2.63	-5.04
Consolidated Net Income / (Loss)	-20	-27	-31	-64	-36	-29	-27	-14	-2.63	-5.04
Depreciation Expense	0.40	0.59	0.59	0.60	0.60	-0.02	0.54	0.44	1.04	0.67
Non-Cash Adjustments To Reconcile Net Income	1.92	1.93	1.52	21	3.13	3.52	5.39	5.46	5.41	4.13
Changes in Operating Assets and Liabilities, net	9.10	7.67	-3.43	10	-6.01	-2.74	-8.29	-11	-10	8.12
Net Cash From Investing Activities	2.52	23	5.07	-93	9.82	28	21	11	4.93	15
Net Cash From Continuing Investing Activities	2.52	23	5.07	-93	9.82	28	21	11	4.93	15
Purchase of Investments	-0.13	-1.08	-10	-103	-90	-34	-98	-78	-86	-14
Sale and/or Maturity of Investments	3.37	24	15	10	100	62	119	89	91	29
Net Cash From Financing Activities	11	6.62	34	92	30	-21	13	0.72	1.18	0.88
Net Cash From Continuing Financing Activities	11	6.62	34	92	30	-21	13	0.72	1.18	0.88
Issuance of Common Equity	11	15	12	136	0.46	0.05	13	0.72	1.18	0.88
Cash Interest Paid	3.21	-	3.05	1.47	-	0.73	0.73	1.02	1.56	3.88

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	133	165	164
Total Current Assets	101	134	134
Cash & Equivalents	74	31	51
Short-Term Investments	23	74	22
Accounts Receivable	0.00	12	34
Inventories, net	0.00	10	20
Prepaid Expenses	2.10	6.61	6.04
Plant, Property, & Equipment, net	0.84	0.59	0.45
Total Noncurrent Assets	31	30	30
Goodwill	17	17	17
Other Noncurrent Operating Assets	13	13	13
Total Liabilities & Shareholders' Equity	133	165	164
Total Liabilities	154	77	90
Total Current Liabilities	56	37	49
Accounts Payable	7.89	11	7.33
Accrued Expenses	7.33	24	41
Other Current Liabilities	2.90	1.20	0.86
Total Noncurrent Liabilities	98	40	42
Other Noncurrent Operating Liabilities	6.52	40	42
Total Equity & Noncontrolling Interests	-21	88	74
Total Preferred & Common Equity	-21	88	74
Preferred Stock	0.01	0.05	0.00
Total Common Equity	-21	88	74
Common Stock	590	856	893
Retained Earnings	-585	-745	-794
Accumulated Other Comprehensive Income / (Loss)	-26	-23	-25

This table presents Avadel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	146	141	201	203	168	158	158
Total Current Assets	113	109	171	172	136	126	127
Cash & Equivalents	61	83	50	52	36	29	29
Short-Term Investments	46	18	111	101	53	43	37
Accounts Receivable	-	-	1.78	6.24	23	33	37
Inventories, net	-	-	1.44	5.29	12	13	16
Prepaid Expenses	4.67	6.26	6.53	6.35	11	6.78	8.25
Plant, Property, & Equipment, net	0.90	0.78	0.72	0.65	0.53	0.48	0.47
Total Noncurrent Assets	32	30	29	30	31	31	31
Goodwill	17	17	17	17	17	17	17
Other Noncurrent Operating Assets	14	12	12	13	14	14	14
Total Liabilities & Shareholders' Equity	146	141	201	203	168	158	158
Total Liabilities	158	179	58	93	90	87	84
Total Current Liabilities	42	79	52	54	48	45	43
Accounts Payable	2.48	10	12	13	19	9.79	7.92
Accrued Expenses	7.97	7.68	18	18	28	34	34
Other Current Liabilities	4.77	41	1.28	1.65	1.21	1.11	0.96
Total Noncurrent Liabilities	117	100	6.28	39	42	43	41
Other Noncurrent Operating Liabilities	6.75	6.41	6.28	39	42	43	41
Total Equity & Noncontrolling Interests	-12	-38	143	110	78	70	75
Total Preferred & Common Equity	-12	-38	143	110	78	70	75
Preferred Stock	0.01	0.01	0.05	0.05	0.00	0.00	0.00
Total Common Equity	-12	-38	143	110	78	70	75
Common Stock	573	604	850	853	875	881	888
Retained Earnings	-558	-616	-680	-717	-773	-787	-789
Accumulated Other Comprehensive Income / (Loss)	-28	-26	-26	-26	-24	-24	-24

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	504.79%
EBITDA Growth	-9.02%	-46.44%	70.20%
EBIT Growth	-15.21%	-39.86%	69.24%
NOPAT Growth	-15.21%	-39.86%	69.24%
Net Income Growth	-77.77%	-16.59%	69.53%
EPS Growth	-73.48%	12.66%	74.50%
Operating Cash Flow Growth	9.06%	-82.79%	63.50%
Free Cash Flow Firm Growth	68.26%	-292.11%	30.17%
Invested Capital Growth	-81.65%	-249.27%	100.41%
Revenue Q/Q Growth	0.00%	228.59%	22.41%
EBITDA Q/Q Growth	2.23%	-3.39%	35.95%
EBIT Q/Q Growth	0.10%	-1.37%	33.75%
NOPAT Q/Q Growth	0.10%	-1.37%	33.75%
Net Income Q/Q Growth	-3.89%	-0.84%	32.72%
EPS Q/Q Growth	-2.69%	7.41%	32.00%
Operating Cash Flow Q/Q Growth	9.22%	-10.93%	43.36%
Free Cash Flow Firm Q/Q Growth	34.88%	-20.44%	37.59%
Invested Capital Q/Q Growth	-32.80%	20.47%	-99.20%
Profitability Metrics	-	-	-
Gross Margin	0.00%	96.97%	90.97%
EBITDA Margin	0.00%	-476.65%	-23.49%
Operating Margin	0.00%	-492.97%	-25.07%
EBIT Margin	0.00%	-492.97%	-25.07%
Profit (Net Income) Margin	0.00%	-573.17%	-28.87%
Tax Burden Percent	123.35%	99.69%	99.50%
Interest Burden Percent	113.07%	116.63%	115.76%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-481.49%	-481.35%	-60.44%
Cash Return on Invested Capital (CROIC)	-45.86%	0.00%	-66,369.44%
Operating Return on Assets (OROA)	0.00%	-92.68%	-25.78%
Return on Assets (ROA)	0.00%	-107.75%	-29.69%
Return on Common Equity (ROCE)	-481.41%	-480.94%	-60.42%
Return on Equity Simple (ROE_SIMPLE)	650.10%	-182.67%	-66.13%
Net Operating Profit after Tax (NOPAT)	-69	-96	-30
NOPAT Margin	0.00%	-345.08%	-17.55%
Net Nonoperating Expense Percent (NNEP)	762.53%	-176.37%	-21.41%
Return On Investment Capital (ROIC_SIMPLE)	-63.80%	-109.98%	-40.19%
Cost of Revenue to Revenue	0.00%	3.03%	9.03%
SG&A Expenses to Revenue	0.00%	542.52%	107.05%
R&D to Revenue	0.00%	47.42%	8.99%
Operating Expenses to Revenue	0.00%	589.94%	116.04%
Earnings before Interest and Taxes (EBIT)	-99	-138	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-91	-133	-40
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	13.71
Price to Tangible Book Value (P/TBV)	0.00	0.00	17.76
Price to Revenue (P/Rev)	0.00	0.00	5.99
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	13,225.11
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	5.55
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-6.11	0.00	0.00
Long-Term Debt to Equity	-4.33	0.00	0.00
Financial Leverage	0.31	-1.09	-1.11
Leverage Ratio	6.66	4.47	2.04
Compound Leverage Factor	7.53	5.21	2.36
Debt to Total Capital	119.55%	0.00%	0.00%
Short-Term Debt to Total Capital	34.83%	0.00%	0.00%
Long-Term Debt to Total Capital	84.72%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.06%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-19.56%	99.94%	100.00%
Debt to EBITDA	-1.42	0.00	0.00
Net Debt to EBITDA	-0.36	0.00	0.00
Long-Term Debt to EBITDA	-1.01	0.00	0.00
Debt to NOPAT	-1.87	0.00	0.00
Net Debt to NOPAT	-0.48	0.00	0.00
Long-Term Debt to NOPAT	-1.33	0.00	0.00
Altman Z-Score	0.00	0.00	0.75
Noncontrolling Interest Sharing Ratio	0.02%	0.09%	0.03%
Liquidity Ratios	-	-	-
Current Ratio	1.81	3.64	2.75
Quick Ratio	1.73	3.18	2.21
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-67	-47
Operating Cash Flow to CapEx	-9,818.99%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-1.39	-2.93	-4.35
Operating Cash Flow to Interest Expense	-5.70	-5.58	-4.33
Operating Cash Flow Less CapEx to Interest Expense	-5.75	-5.58	-4.33
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.19	1.03
Accounts Receivable Turnover	0.00	0.00	7.32
Inventory Turnover	0.00	0.00	1.00
Fixed Asset Turnover	0.00	39.27	325.85
Accounts Payable Turnover	0.00	0.09	1.63
Days Sales Outstanding (DSO)	0.00	0.00	49.86
Days Inventory Outstanding (DIO)	0.00	0.00	366.48
Days Payable Outstanding (DPO)	0.00	4,168.38	224.12
Cash Conversion Cycle (CCC)	0.00	-4,168.38	192.22
Capital & Investment Metrics	-	-	-
Invested Capital	12	-17	0.07
Invested Capital Turnover	0.00	-9.75	-19.55
Increase / (Decrease) in Invested Capital	-52	-29	17
Enterprise Value (EV)	0.00	0.00	939
Market Capitalization	0.00	0.00	1,013
Book Value per Share	($0.34)	$0.98	$0.77
Tangible Book Value per Share	($0.61)	$0.79	$0.59
Total Capital	108	88	74
Total Debt	129	0.00	0.00
Total Long-Term Debt	92	0.00	0.00
Net Debt	33	-105	-74
Capital Expenditures (CapEx)	0.72	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-7.76	12
Debt-free Net Working Capital (DFNWC)	83	97	85
Net Working Capital (NWC)	45	97	85
Net Nonoperating Expense (NNE)	68	64	19
Net Nonoperating Obligations (NNO)	33	-105	-74
Total Depreciation and Amortization (D&A)	7.55	4.56	2.68
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-27.77%	6.86%
Debt-free Net Working Capital to Revenue	0.00%	348.13%	50.48%
Net Working Capital to Revenue	0.00%	348.13%	50.48%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.29)	($2.00)	($0.51)
Adjusted Weighted Average Basic Shares Outstanding	60.09M	80.17M	95.14M
Adjusted Diluted Earnings per Share	($2.29)	($2.00)	($0.51)
Adjusted Weighted Average Diluted Shares Outstanding	60.09M	80.17M	95.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	64.48M	90.58M	96.63M
Normalized Net Operating Profit after Tax (NOPAT)	-67	-96	-30
Normalized NOPAT Margin	0.00%	-345.08%	-17.55%
Pre Tax Income Margin	0.00%	-574.96%	-29.02%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-7.99	-5.99	-3.92
NOPAT to Interest Expense	-5.59	-4.19	-2.74
EBIT Less CapEx to Interest Expense	-8.04	-5.99	-3.92
NOPAT Less CapEx to Interest Expense	-5.65	-4.19	-2.74
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Avadel Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,674.33%	613.22%	159.14%
EBITDA Growth	41.79%	9.18%	7.91%	-74.10%	-133.45%	-21.27%	1.33%	74.55%	102.07%	89.45%
EBIT Growth	33.91%	0.42%	1.15%	-65.48%	-107.02%	-8.08%	8.00%	74.28%	99.07%	86.76%
NOPAT Growth	33.91%	0.42%	1.15%	-65.48%	-107.02%	-8.08%	8.00%	74.28%	99.07%	86.76%
Net Income Growth	8.44%	-23.09%	-16.50%	-1.56%	-80.06%	-4.87%	11.18%	78.55%	92.76%	82.48%
EPS Growth	13.16%	-15.79%	-6.67%	22.43%	-24.24%	36.36%	37.50%	83.13%	92.68%	85.71%
Operating Cash Flow Growth	67.97%	31.72%	11.20%	-127.27%	-461.90%	-82.41%	1.75%	43.21%	81.98%	128.09%
Free Cash Flow Firm Growth	373.42%	438.25%	472.35%	-213.58%	-52.59%	-67.52%	-141.52%	62.19%	-312.07%	-270.55%
Invested Capital Growth	-71.11%	-81.65%	-134.16%	-86.85%	-226.13%	-249.27%	59.09%	-130.97%	140.54%	100.41%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	368.85%	177.35%	39.71%	52.71%	20.53%	0.77%
EBITDA Q/Q Growth	47.28%	-40.34%	-25.75%	-87.15%	29.31%	27.10%	-2.31%	51.74%	105.75%	-471.19%
EBIT Q/Q Growth	43.35%	-35.84%	-22.83%	-75.07%	29.13%	29.08%	-4.56%	51.06%	97.43%	-907.95%
NOPAT Q/Q Growth	43.35%	-35.84%	-22.83%	-75.07%	29.13%	29.08%	-4.56%	51.06%	97.43%	-907.95%
Net Income Q/Q Growth	68.25%	-36.26%	-12.15%	-109.30%	43.70%	20.64%	5.02%	49.45%	81.01%	-92.11%
EPS Q/Q Growth	69.16%	-33.33%	-9.09%	-72.92%	50.60%	31.71%	-7.14%	53.33%	78.57%	-33.33%
Operating Cash Flow Q/Q Growth	51.72%	-125.87%	-96.75%	-5.92%	-19.37%	26.68%	-5.98%	38.78%	62.11%	214.27%
Free Cash Flow Firm Q/Q Growth	207.81%	15.91%	124.61%	-114.17%	228.50%	-20.60%	-387.17%	87.09%	-620.64%	36.14%
Invested Capital Q/Q Growth	-35.53%	-32.80%	-318.55%	113.89%	-718.26%	20.47%	40.10%	89.49%	909.51%	-99.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	97.59%	98.33%	96.44%	94.40%	93.28%	87.70%	90.45%
EBITDA Margin	0.00%	0.00%	0.00%	-3,232.15%	-487.30%	-128.09%	-93.80%	-29.65%	1.42%	-5.21%
Operating Margin	0.00%	0.00%	0.00%	-3,311.56%	-500.57%	-128.00%	-95.79%	-30.70%	-0.65%	-6.54%
EBIT Margin	0.00%	0.00%	0.00%	-3,311.56%	-500.57%	-128.00%	-95.79%	-30.70%	-0.65%	-6.54%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-4,306.95%	-517.17%	-147.98%	-100.60%	-33.30%	-5.25%	-10.00%
Tax Burden Percent	100.35%	100.31%	98.15%	100.14%	100.25%	99.65%	100.34%	96.45%	103.47%	101.63%
Interest Burden Percent	118.37%	118.78%	110.83%	129.88%	103.06%	116.01%	104.66%	112.48%	775.84%	150.55%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-228.19%	0.00%	0.00%	0.00%	-1,676.62%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-173.83%	0.00%	0.00%	0.00%	-1,671.97%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	136.05%	0.00%	0.00%	0.00%	1,652.87%	0.00%	0.00%
Return on Equity (ROE)	-305.87%	-481.49%	-1,662.06%	-92.14%	-325.33%	-481.35%	-779.92%	-23.75%	-78.54%	-60.44%
Cash Return on Invested Capital (CROIC)	-68.41%	-45.86%	0.00%	-389.25%	0.00%	0.00%	0.00%	0.00%	-852.54%	-66,369.44%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-27.61%	-24.42%	-24.06%	-34.23%	-16.30%	-0.50%	-6.72%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-35.90%	-25.23%	-27.82%	-35.95%	-17.68%	-4.01%	-10.29%
Return on Common Equity (ROCE)	-305.84%	-481.41%	-1,661.09%	-92.10%	-325.14%	-480.94%	-779.82%	-23.74%	-78.52%	-60.42%
Return on Equity Simple (ROE_SIMPLE)	1,063.63%	0.00%	371.60%	-99.73%	-144.30%	0.00%	-200.08%	-151.13%	-97.20%	0.00%
Net Operating Profit after Tax (NOPAT)	-12	-16	-20	-35	-25	-17	-18	-8.92	-0.23	-2.31
NOPAT Margin	0.00%	0.00%	0.00%	-2,318.09%	-350.40%	-89.60%	-67.06%	-21.49%	-0.46%	-4.58%
Net Nonoperating Expense Percent (NNEP)	-178.92%	126.10%	68.68%	-54.36%	-22.88%	-31.40%	-23.98%	-4.65%	-2.42%	-3.06%
Return On Investment Capital (ROIC_SIMPLE)	-	-14.91%	-	-	-	-19.87%	-	-	-	-3.12%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	2.41%	1.67%	3.56%	5.60%	6.72%	12.30%	9.55%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	3,126.87%	558.28%	212.31%	178.91%	114.22%	80.75%	88.51%
R&D to Revenue	0.00%	0.00%	0.00%	282.29%	40.62%	12.13%	11.29%	9.76%	7.60%	8.48%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	3,409.16%	598.90%	224.44%	190.19%	123.98%	88.35%	96.99%
Earnings before Interest and Taxes (EBIT)	-17	-23	-28	-50	-35	-25	-26	-13	-0.33	-3.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-21	-26	-48	-34	-25	-25	-12	0.71	-2.63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.23	16.91	13.71
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.28	21.83	17.76
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.20	9.14	5.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	135.14	13,225.11
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.45	8.66	5.55
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-10.95	-6.11	-2.98	0.15	0.19	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	-8.84	-4.33	-2.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.11	0.31	1.87	-0.78	-1.05	-1.09	-1.89	-0.99	-1.07	-1.11
Leverage Ratio	4.74	6.66	21.20	2.57	3.57	4.47	7.67	1.68	1.96	2.04
Compound Leverage Factor	5.61	7.91	23.50	3.33	3.68	5.18	8.03	1.89	15.17	3.06
Debt to Total Capital	110.05%	119.55%	150.56%	12.71%	16.13%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	21.24%	34.83%	27.18%	12.71%	16.13%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	88.80%	84.72%	123.38%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.01%	0.03%	0.04%	0.06%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-10.05%	-19.56%	-50.57%	87.26%	83.83%	99.94%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-1.46	-1.42	-1.28	-0.19	-0.16	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.32	-0.36	-0.14	1.28	1.02	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-1.18	-1.01	-1.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.97	-1.87	-1.65	-0.25	-0.22	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-0.43	-0.48	-0.19	1.69	1.39	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.59	-1.33	-1.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-4.01	0.00	0.00	0.00	0.00	0.00	0.00	3.26	3.59	1.54
Noncontrolling Interest Sharing Ratio	0.01%	0.02%	0.06%	0.04%	0.06%	0.09%	0.01%	0.02%	0.03%	0.03%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.73	1.81	1.38	3.32	3.19	3.64	2.85	2.82	2.97	2.75
Quick Ratio	2.57	1.73	1.27	3.15	2.95	3.18	2.33	2.35	2.41	2.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	31	36	80	-11	15	12	-33	-4.29	-31	-20
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	8.63	10.95	24.57	-0.74	7.37	4.92	-12.83	-1.58	-10.97	-7.31
Operating Cash Flow to Interest Expense	-1.91	-4.72	-9.28	-2.08	-19.33	-11.91	-11.46	-6.70	-2.44	2.91
Operating Cash Flow Less CapEx to Interest Expense	-1.91	-4.72	-9.28	-2.08	-19.33	-11.91	-11.46	-6.70	-2.44	2.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.01	0.05	0.19	0.36	0.53	0.76	1.03
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	6.38	7.32
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.69	1.04	1.00
Fixed Asset Turnover	0.00	0.00	0.00	3.09	11.02	39.27	84.31	158.71	247.38	325.85
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.02	0.09	0.16	0.47	1.05	1.63
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.42	57.25	49.86
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	525.83	349.74	366.48
Days Payable Outstanding (DPO)	0.00	0.00	0.00	96,846.67	18,777.22	4,168.38	2,233.78	769.21	346.42	224.12
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-96,846.67	-18,777.22	-4,168.38	-2,233.78	-175.96	60.57	192.22
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	17	12	-25	3.53	-22	-17	-10	-1.09	8.86	0.07
Invested Capital Turnover	0.00	0.00	0.00	0.10	-3.76	-9.75	-3.08	78.02	-21.28	-19.55
Increase / (Decrease) in Invested Capital	-43	-52	-100	-23	-39	-29	15	-4.63	31	17
Enterprise Value (EV)	329	0.00	0.00	0.00	0.00	0.00	0.00	1,280	1,197	939
Market Capitalization	300	0.00	0.00	0.00	0.00	0.00	0.00	1,351	1,263	1,013
Book Value per Share	($0.21)	($0.34)	($0.59)	$1.86	$1.23	$0.98	$0.87	$0.73	$0.78	$0.77
Tangible Book Value per Share	($0.49)	($0.61)	($0.85)	$1.65	$1.04	$0.79	$0.68	$0.56	$0.60	$0.59
Total Capital	124	108	75	164	131	88	78	70	75	74
Total Debt	136	129	114	21	21	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	110	92	93	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	30	33	13	-140	-132	-105	-89	-71	-66	-74
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.47	-14	-50	-20	-14	-7.76	-0.56	9.79	19	12
Debt-free Net Working Capital (DFNWC)	98	83	51	141	139	97	88	81	84	85
Net Working Capital (NWC)	72	45	30	120	118	97	88	81	84	85
Net Nonoperating Expense (NNE)	8.27	11	11	30	12	11	9.12	4.90	2.40	2.74
Net Nonoperating Obligations (NNO)	30	33	13	-140	-132	-105	-89	-71	-66	-74
Total Depreciation and Amortization (D&A)	2.32	2.49	2.46	1.19	0.93	-0.02	0.54	0.44	1.04	0.67
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-1,332.29%	-162.06%	-27.77%	-1.02%	10.28%	13.51%	6.86%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	9,396.99%	1,637.93%	348.13%	160.00%	85.31%	61.14%	50.48%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	8,003.21%	1,388.97%	348.13%	160.00%	85.31%	61.14%	50.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.44)	($0.48)	($0.83)	($0.41)	($0.28)	($0.30)	($0.14)	($0.03)	($0.04)
Adjusted Weighted Average Basic Shares Outstanding	60.20M	60.09M	63.89M	77.25M	89.38M	80.17M	91.69M	96.15M	96.30M	95.14M
Adjusted Diluted Earnings per Share	($0.33)	($0.44)	($0.48)	($0.83)	($0.41)	($0.28)	($0.30)	($0.14)	($0.03)	($0.04)
Adjusted Weighted Average Diluted Shares Outstanding	60.20M	60.09M	63.89M	77.25M	89.38M	80.17M	91.69M	96.15M	96.30M	95.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.78M	64.48M	76.77M	89.37M	89.81M	90.58M	96.12M	96.27M	96.36M	96.63M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-16	-20	-35	-25	-17	-18	-8.92	-0.23	-2.31
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-2,318.09%	-350.40%	-89.60%	-67.06%	-21.49%	-0.46%	-4.58%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-4,300.94%	-515.90%	-148.49%	-100.26%	-34.53%	-5.07%	-9.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.76	-7.08	-8.68	-3.21	-17.75	-10.58	-10.04	-4.69	-0.12	-1.22
NOPAT to Interest Expense	-3.33	-4.95	-6.08	-2.25	-12.43	-7.40	-7.03	-3.28	-0.08	-0.85
EBIT Less CapEx to Interest Expense	-4.76	-7.08	-8.68	-3.21	-17.75	-10.58	-10.04	-4.69	-0.12	-1.22
NOPAT Less CapEx to Interest Expense	-3.33	-4.95	-6.08	-2.25	-12.43	-7.40	-7.03	-3.28	-0.08	-0.85
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

When does Avadel Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Avadel Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Avadel Pharmaceuticals' net income changed over the last 2 years?

Avadel Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$48.83 million in 2024, falling from -$137.46 million in 2022. The previous period was -$160.28 million in 2023. Find out what analysts predict for Avadel Pharmaceuticals in the coming months.

What is Avadel Pharmaceuticals's operating income?

Avadel Pharmaceuticals's total operating income in 2024 was -$42.40 million, based on the following breakdown:

Total Gross Profit: $153.84 million
Total Operating Expenses: $196.24 million

How has Avadel Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Avadel Pharmaceuticals' total revenue changed from $0.00 in 2022 to $169.12 million in 2024, a change of 16,911,700,000.0%.

How much debt does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals' total liabilities were at $90.39 million at the end of 2024, a 17.4% increase from 2023, and a 41.3% decrease since 2022.

How much cash does Avadel Pharmaceuticals have?

In the past 2 years, Avadel Pharmaceuticals' cash and equivalents has ranged from $31.17 million in 2023 to $73.98 million in 2022, and is currently $51.37 million as of their latest financial filing in 2024.

How has Avadel Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Avadel Pharmaceuticals' book value per share changed from -0.34 in 2022 to 0.77 in 2024, a change of -323.8%.

Related Companies

This page (NASDAQ:AVDL) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avadel Pharmaceuticals (AVDL) Financials

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avadel Pharmaceuticals (AVDL) Financials

Annual Income Statements for Avadel Pharmaceuticals

Quarterly Income Statements for Avadel Pharmaceuticals

Annual Cash Flow Statements for Avadel Pharmaceuticals

Quarterly Cash Flow Statements for Avadel Pharmaceuticals

Annual Balance Sheets for Avadel Pharmaceuticals

Quarterly Balance Sheets for Avadel Pharmaceuticals

Annual Metrics and Ratios for Avadel Pharmaceuticals

Quarterly Metrics and Ratios for Avadel Pharmaceuticals

Frequently Asked Questions About Avadel Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools